CUTANEOUS ADVERSE EVENTS IN CHILDREN TREATED WITH BRAF-INHIBITOR VEMURAFENIB FOR REFRACTORY BRAF (V600E) MUTATED LANGERHANS CELL HISTIOCYTOSIS: A EUROPEAN COHORT STUDY
https://www.hal.inserm.fr/inserm-02413491
Contributor : Valerie Taly <>
Submitted on : Monday, December 16, 2019 - 11:21:27 AM Last modification on : Friday, December 11, 2020 - 3:20:34 AM
Mathilde Tardieu, Sophie Duvert Lehembre, Islam Amine Larabi, Johannes Visser, Caroline Hutter, et al.. CUTANEOUS ADVERSE EVENTS IN CHILDREN TREATED WITH BRAF-INHIBITOR VEMURAFENIB FOR REFRACTORY BRAF (V600E) MUTATED LANGERHANS CELL HISTIOCYTOSIS: A EUROPEAN COHORT STUDY. 34th Annual Meeting of the Histiocyte Society Lisbon, Portugal, October 22–23, 2018, Oct 2019, Lisbon, Portugal. pp.S46-S47. ⟨inserm-02413491⟩